ArticleBulletin of the World Health Organization2018
Hepatitis B and C virus seroprevalence, Burkina Faso: a cross-sectional study.
Article in Bulletin of the World Health Organization, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Epidemiologic profile of hepatitis C virus infection and genotype distribution in Burkina Faso: a systematic review with meta-analysis.BMC infectious diseases · 2021Pooled it
- Article
- Immune response to GeneVac-BIJID regions · 2024Article
- Seroprevalence of hepatitis C, hepatitis B, hiv and syphilis among blood donors at a tertiary care hospital in Mogadishu-Somalia in 2020-2022: a retrospective study.BMC public health · 2024Article
- The prevalence of hepatitis C virus genotypes and factors associated with cirrhosis, fatty liver, and viral load: A registry-based cross-sectional cohort study in Western Iran during 1999-2023.Health science reports · 2024Article
- Genetic diversity and occult hepatitis B infection in Africa: A comprehensive review.World journal of hepatology · 2024Article
- Identification of associated risk factors for serological distribution of hepatitis B virus via machine learning models.BMC infectious diseases · 2024Article
- Prevalence and risk factors of Hepatitis C virus infection in the Upper East Region of Ghana; a community-based cross-sectional study.PloS one · 2024Article
- Evaluation of the Diagnostic Performances of the SD-BiolineDiagnostics (Basel, Switzerland) · 2023Article
- Intermediate hepatitis B virus infection prevalence among 1622 pregnant women in rural Burkina Faso and implications for mother-to-child transmission.Scientific reports · 2023Article
- Residual risk of hepatitis B virus transmission through blood donations in Burkina Faso screened with rapid diagnostic tests.Health science reports · 2022Article
- Methods and indicators to validate country reductions in incidence of hepatitis C virus infection to elimination levels set by WHO.The lancet. Gastroenterology & hepatology · 2022Review
- Screening for Hepatitis B in partners and children of women positive for surface antigen, Burkina Faso.Bulletin of the World Health Organization · 2022Article
- Alcohol consumption and associated risk factors in Burkina Faso: results of a population-based cross-sectional survey.BMJ open · 2022Article
- Seroprevalence, Genotyping, and Monitoring of Hepatitis C Viral Loads in Patients on Antivirals in Burkina Faso.Intervirology · 2022Article
- Chronic viral hepatitis, HIV infection and Non-Hodgkin lymphomas in West Africa, a case-control study.International journal of cancer · 2021Article
- Prevalence of viral hepatitis B and C in Sierra Leone-current knowledge and knowledge gaps: a narrative review.Transactions of the Royal Society of Tropical Medicine and Hygiene · 2021Review
- Elimination of Viral Hepatitis in Low and Middle-Income Countries: Epidemiological Research Gaps.Current epidemiology reports · 2021Article
- The global burden of chronic hepatitis B virus infection: comparison of country-level prevalence estimates from four research groups.International journal of epidemiology · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo estimate population-wide hepatitis B and C seroprevalence using dried blood spot samples acquired for human immunodeficiency virus (HIV) surveillance as part of the 2010-2011 Demographic and Health Survey in Burkina Faso.
methodsWe used the database acquired during the multistage, clustered, population-based survey, in which 15 377 participants completed questionnaires and provided dried blood spot samples for HIV testing. We extracted sociodemographic and geographic data including age, sex, ethnicity, education, wealth, marital status and region for each participant. We performed hepatitis B and C assays on 14 886 HIV-negative samples between March to October 2015, and calculated weighted percentages of hepatitis seroprevalence for each variable.
findingsWe estimated seroprevalence as 9.1% (95% confidence interval, CI: 8.5-9.7) for the hepatitis B surface antigen and 3.6% (95% CI: 3.3-3.8) for hepatitis C virus antibodies, classifying Burkina Faso as highly endemic for hepatitis B and low-intermediate for hepatitis C. The seroprevalence of hepatitis was higher in men than in women, and varied significantly for both with age, education, ethnicity and region. Extremely high HCV-Ab seroprevalence (13.2%; 95% CI: 10.6-15.7) was identified in the Sud-Ouest region, in particular within the youngest age group (15-20 years), indicating an ongoing epidemic.
conclusionOur population-representative hepatitis seroprevalence estimates in Burkina Faso advocate for the inclusion of hepatitis serological tests and risk factor questionnaire items in future surveys, the results of which are crucial for the development of appropriate health policies and infection control programmes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.